Lindsay Clancy Case Highlights Systemic Failures in Perinatal Mental Health Care

One to two women per 1,000 births develop postpartum psychosis—a rare but life-threatening condition requiring immediate psychiatric evaluation and often hospitalization, according to research cited by Sit et al. (2006) and the American College of Obstetricians and Gynecologists (ACOG, 2023). The Lindsay Clancy case, in which three young children died, has intensified national focus on this disorder and exposed systemic challenges in recognizing and managing severe perinatal psychiatric illness before crisis.

What Is Postpartum Psychosis?

Postpartum psychosis differs clinically from postpartum depression. It may include hallucinations, delusions, profound confusion, insomnia, mood instability, disorganized thinking, and loss of contact with reality. Untreated, it carries elevated risks of harm to self or infant (ACOG, 2023). Yet most individuals with perinatal mood disorders never harm themselves or their children. Sensationalized media coverage can unintentionally increase stigma and deter mothers from reporting distressing symptoms due to fears of judgment, involuntary hospitalization, or custody loss (ACOG, 2023).

When Standard Treatments Fail

Courtroom testimony in the Clancy trial highlighted a broader clinical reality: medication- or treatment-resistant psychiatric illness. Although antidepressants have helped millions, they are not universally effective. Approximately one-third of people diagnosed with major depressive disorder fail to achieve remission after multiple medication trials (McAllister-Williams et al., 2020). Causes of such failure may include misdiagnosis, suboptimal dosing, intolerable side effects, paradoxical symptom worsening, or the need for an entirely different therapeutic framework.

Clinicians must reassess—not persist—with unchanged strategies when patients deteriorate or show no improvement. Individualized care remains central to psychiatry, as it is across medicine.

Evidence-Based Alternatives Under Discussion

Public testimony indicated Lindsay Clancy raised the possibility of ketamine treatment with her psychiatrist. She was told insurance coverage required prior failure on four distinct antidepressants. Whether alternative treatment decisions would have altered the outcome cannot be determined from available evidence and falls within the legal process—not clinical speculation.

Still, the case underscores systemic gaps: limited awareness among patients and providers about evidence-based options for treatment-resistant illness, and restrictive insurance policies that delay or block access. Among those options are:

• Electroconvulsive Therapy (ECT): Modern ECT is among the most effective interventions for severe depression with psychotic features, catatonia, or treatment resistance. It can produce rapid, life-saving improvement where traditional antidepressants fall short (American Psychiatric Association, 2021).
• Ketamine and Esketamine: Research over the past decade shows ketamine-based therapies can yield rapid reductions in depressive symptoms and suicidal ideation for some individuals with treatment-resistant depression. Their use requires careful psychiatric oversight but represents a major advance (Alipoor et al., 2021; McIntyre et al., 2021).
• Other evidence-based approaches include transcranial magnetic stimulation (TMS), intensive outpatient or partial hospitalization programs, reproductive psychiatry consultation, and multidisciplinary treatment teams—each tailored to individual presentation.

The issue is not universal application of these treatments. It is ensuring every patient receives a comprehensive evaluation of all evidence-based options when conventional approaches fail.

The Cumulative Impact of Delay

Mental health deterioration often unfolds gradually. Families may interpret worsening symptoms as stress or fatigue. Patients may minimize their own distress. Clinicians may anchor interpretations to earlier diagnoses. Insurance authorization requirements can stall referrals to specialized care.

Each delay may appear minor in isolation. Together, they compound—while psychiatric conditions evolve. Treatment plans must evolve accordingly.

Toward Earlier Intervention

This tragedy extends beyond the courtroom. It calls for:

• Greater public education about postpartum psychiatric disorders;
• Expanded access to reproductive psychiatrists and mother-baby psychiatric programs where available;
• Insurance systems that support clinical judgment—not rigid algorithms—when patients rapidly decline;
• Ongoing research into mechanisms of treatment resistance and safe integration of emerging therapies;
• Recognition that psychiatric illness is fundamentally a brain-based medical condition—like heart disease or cancer—where early recognition and timely intervention significantly influence outcomes.

No one can determine whether different clinical decisions would have changed the course of events in this case. The family did not receive that opportunity.

What remains actionable now is using this tragedy to drive improvements in education, early identification, care access, and awareness of the full spectrum of evidence-based treatments. Lives depend on clinicians, families, policymakers, insurers, and the public gaining deeper understanding of severe postpartum psychiatric illness—and the interventions proven to address it.